Company to Provide Update on cGMP Manufacturing Facility and Bacteriophage Cocktail Therapy for Treating S. aureus
Public Company Information:
SAN DIEGO & RICHMOND, Va. & LJUBLJANA, Slovenia & SYDNEY--(BUSINESS WIRE)--AmpliPhi BioSciences Corporation (OTCQB:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that the Company will give a presentation today at the 21st Biennial Evergreen International Phage Meeting, taking place August 2-7 in Olympia, Wash.
Sandra Morales, Ph.D., AmpliPhi’s Vice President of Research, will lead a discussion entitled ‘GMP phage production for clinical trials,’ describing the Company’s dedicated current good manufacturing practices (cGMP)-certified manufacturing facility and will provide an overview on AmpliPhi’s investigational bacteriophage cocktail for treating Staphylococcus aureus infections. The presentation will take place today, Wednesday August 5 at 1:20 PM PDT.
“We were pleased to announce in June that AmpliPhi received cGMP certification for its manufacturing facility, the first in the world solely dedicated to producing bacteriophage products for human use,” said M. Scott Salka, CEO of AmpliPhi. “Following achievement of this significant milestone, the Company is in a strong position to manufacture novel bacteriophage-based treatments to combat the growing global epidemic of antibacterial resistance, and we can now do so at commercial scale, in a safe, efficient and highly reproducible manner.”
As part of AmpliPhi’s commitment to developing and commercializing novel bacteriophage-based antibacterial therapeutics, the Company has provided the conference with a sponsorship grant that will be used to support young scientists and meeting participants from underdeveloped countries.
“This is an exciting time in the development of human phage-based therapies and we are proud to celebrate the 21st Biennial International Phage Meeting with more than 200 attendees from 40 countries,” said Betty Kutter, Ph.D., Evergreen Faculty Emerita, and Director of the Evergreen Phage Lab. “We are also encouraged by recent government commitments to combatting antibacterial resistance and are grateful to the support of this meeting from the USDA and NIH. We are pleased to honor AmpliPhi Biosciences as a collaborative supporter of the phage community. We look forward to following the Company’s progress in advancing much-needed phage treatments to the clinic.”
About AmpliPhi BioSciences
AmpliPhi BioSciences Corporation (OTCQB: APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. The Company's product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation (NYSE: XON), the U.S. Army, The Royal Brompton Clinic in London, UK and UK-based University of Leicester, to rapidly advance bacteriophage-based therapies. For more information, visit www.ampliphibio.com.
Bacteriophage are naturally occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophage are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defense for bacteria, contributing to antibiotic resistance. Bacteriophage are able to penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects.
Forward Looking Statements
Statements in this press release about the potential use of bacteriophages to treat bacterial infections, the Company’s manufacturing plans and capability, and the development of bacteriophage-based therapies are forward looking statements subject to risks and uncertainties, including without limitation the risk that the Company will not be able to successfully manufacture sufficient quantities of products to conduct clinical trials or commercialize products in a timely manner or at all, that AmpliPhi may not commence clinical trials or complete IND-enabling studies as expected, that the clinical trials will not be successful, that further development of the Company's products will require extensive and expensive nonclinical and clinical testing, may not be safe or efficacious, and may not be approved for marketing by the United States Food and Drug Administration or any foreign regulatory agency. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to AmpliPhi's business in general, see AmpliPhi's Annual Report on Form 10-K for the fiscal year ended December 31, 2014, as amended, filed with the Securities and Exchange Commission (SEC) on April 15, 2015.
Company and Investor Relations:
Baxter Phillips III, +1-804-754-5442
Chief Business Officer
Media Relations (USA):
Danielle Lewis/Glenn Silver
+ 1 212-867-1762
Media Relations (Europe and ROW):
Gemma Howe/Sue Charles/Daniel Gooch
+44 (0)20 7866 7905